ConductScience.org, home

Gene · 29904

EEF2K: eukaryotic elongation factor 2 kinase

12 sourcesgene-search-2026-11-11-0.2.0

Download JSON
Cite this record

ConductScience Library. EEF2K: eukaryotic elongation factor 2 kinase. Genes, record 29904. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/29904

On this page

Gene

Symbol
EEF2K
HGNC
Name
eukaryotic elongation factor 2 kinase
HGNC
NCBI Gene ID
29904
NCBI Gene
HGNC ID
HGNC:24615
HGNC
Ensembl
ENSG00000103319
NCBI Gene
Aliases
CaMKIII, HSU93850, eEF-2K
NCBI Gene
Type
protein-coding
NCBI Gene

Proteins1

Reviewed human proteins whose Swiss-Prot entry states the gene.

UniProt entryProteinLengthStructuresGene stated in
O00418Eukaryotic elongation factor 2 kinase72510Ensembl, GeneID, HGNC

Source UniProt

Patents13

Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.

PublicationPublishedSEQ ID NOProteinSource
JP 2026004568 A2026-01-1445395O00418Espacenet
EP 4641201 A22025-10-291722O00418Espacenet
JP 2025517969 A2025-06-121722O00418Espacenet
US 11446398 B22022-09-2028467O00418Espacenet
JP 2022524081 A2022-04-27131438O00418Espacenet
WO 2020043864 A12020-03-05758O00418Espacenet
JP 2019054813 A2019-04-11225830O00418Espacenet
JP 2017121241 A2017-07-13225830O00418Espacenet
JP 2015516143 A2015-06-08225830O00418Espacenet
WO 2013190075 A22013-12-27980O00418Espacenet

1 to 10 of 13

See all 13 patents

Drugs0

Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.

None in this release.

Trials0

Trials of those drugs. A trial joins the gene only through a drug that acts on it.

None in this release.

NIH grants1,048

NIH grants whose papers are about the gene, through NIH's grant-paper links.

GrantTitleEEF2K papersNewest fiscal year
P30CA016672Cancer Center Support Grant202025
R01MH070727Antidepressants and Intracellular Signaling Linked to BDNF102025
ZIAMH002857Glutamatergic Modulators for Rapid and Sustained Antidepressant Effect72025
P30CA072720Cancer Center Support Grant62025
ZIAMH002927Neurobiology and Target Validation of Novel Therapeutic Agents in Mood Disorders62025
P30CA008748Cancer Center Support Grant52025
P30AG072947Alzheimer's Disease Research Center42025
UL1TR001863Yale Clinical and Translational Science Award42025
P30CA012197Cancer Center Support Grant32025
P50HD103537Overall: Eunice Kennedy Shriver Intellectual and Developmental Disabilities Research Center at Vanderbilt32025

1 to 10 of 1,048Source NIH's project files

See all 1,048 nih grants

Papers1,500

Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.

TitleJournalYearPMIDFound bySource
Drugging non-canonical kinases in cancer therapeutics: Molecular targets, underlying mechanisms and small-molecule inhibitors.Acta Pharm Sin B202642453394PubTator, text miningPubMed
Erratum to: Calcium/Calmodulin-Dependent Protein Kinase II and Eukaryotic Elongation Factor 2 Kinase Pathways Mediate the Antidepressant Action of Ketamine.Biol Psychiatry202642446461PubTator, text miningPubMed
Synaptic Plasticity-Intrinsic Excitability and Antidepressant Discovery.Biomedicines202642351693PubTator, text miningPubMed
Emodin inhibits Newcastle disease virus replication via regulating the phosphorylation levels of eEF2K/eEF2 and targeting viral N protein to reduce viral protein production.Poult Sci202642241768PubTator, text miningPubMed
Integrative Transcriptomic Analysis Identifies Shared Immune-Fibrotic Transcriptional Programs Across Crohn's Disease and Idiopathic Pulmonary Fibrosis.Int J Mol Sci202642196408PubTator, text miningPubMed
Tumor-Suppressive microRNA Therapy Inhibits Growth of Glioblastoma Multiforme Xenografts.Cancers (Basel)202642122275PubTator, text miningPubMed
Targeting eukaryotic elongation factor 2 (eEF2)/eEF2 kinase in neurological and neuropsychiatric Disorders: Mechanisms, therapeutic Implications, and translational challenges.Brain Res202642092578PubTator, text miningPubMed
eEF2K-Mediated Stabilization of PCBP2 Promotes Oncogenic mRNA Programs in Triple-Negative Breast Cancer.Int J Biol Sci202642003905PubTator, text miningPubMed
Disrupting PQBP1-eEF2 protein-protein interaction: From synaptic translation to immunity and cancer.Neurochem Int202641960772PubTator, text miningPubMed
Computational discovery and preclinical validation of a novel nanodrug eEF2 kinase inhibitor for suppression of tumor growth in triple-negative breast cancer by induction of ferroptosis and apoptosis.Int J Biol Macromol202641951086PubTator, text miningPubMed

1 to 10 of 1,500

See all 1,500 papers

Sources 12

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
  • GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
  • HGNCCC0
  • NCBI GenePublic domain (US government)
  • NIH's project files and grant-paper linksPublic domain
  • Open TargetsCC0 1.0
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
  • GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
  • HGNCCC0: https://www.genenames.org/about/license/
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this gene from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/genes/v1/29904

GET https://conductscience.org/api/genes/v1/29904/patents